G1 Therapeutics, Inc. clinical trials

Acquired by Pharmacosmos A/S, Sep 18, 2024 · source ↗

The registry lists 16 studies whose lead sponsor is G1 Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 21, 2026.

Before and after it joined Pharmacosmos A/S

First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S: 16
First submitted after G1 Therapeutics, Inc. became part of Pharmacosmos A/S: 0
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 9
Terminated: 5
Approved for marketing: 1
Status unknown: 1

Phase

Phase 2: 10
Phase 1: 7
Phase 3: 2

Where

United States: 12
Bulgaria: 5
Georgia: 5
Spain: 5
France: 4
Ukraine: 4

Registry sponsor names on this page

G1 Therapeutics, Inc.16 studies

Something wrong with this grouping? Tell us on the Pharmacosmos A/S page.

Studies

Recruiting first, then most recently updated. Showing 16 of 16. All Pharmacosmos A/S studies →

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast CancerCompletedNCT03455270Phase 1
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLCCompletedNCT03041311Phase 2
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan ChemotherapyCompletedNCT02514447Phase 1/2
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then AvelumabTerminatedNCT04887831Phase 2
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast CancerTerminatedNCT05113966Phase 2
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):TerminatedNCT04607668Phase 3
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)CompletedNCT04799249Phase 3
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast CancerCompletedNCT05112536Phase 2
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung CancerCompletedNCT03455829Phase 1/2
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)TerminatedNCT04863248Phase 2
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerStatus unknownNCT02983071Phase 1/2
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)TerminatedNCT02978716Phase 2
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung CancerApproved for marketingNCT04504513
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)CompletedNCT02499770Phase 1/2
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1CompletedNCT02243150Phase 1
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S
First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy VolunteersCompletedNCT02821624Phase 1
Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S